Ticagrelor,
does it really help with Reduced composite risk of cardiovascular death, myocardial infarction, or stroke and reduced all-cause mortality versus clopidogrel when combined with aspirin in acute coronary syndrome?
research showsTicagrelor is rated A because a very large hard-endpoint randomized trial showed lower composite cardiovascular events and all-cause mortality than clopidogrel when each was combined with aspirin for acute coronary syndrome. Among 18,624 PLATO participants, the 12-month primary composite occurred in 9.8% versus 11.7%, HR 0.84 (95% CI 0.77 to 0.92), and all-cause death occurred in 4.5% versus 5.9%, HR 0.78 (95% CI 0.69 to 0.89). Overall PLATO-defined major bleeding was not significantly different at 11.6% versus 11.2%, but non-CABG major bleeding, fatal intracranial bleeding, dyspnea, and bradyarrhythmic events require attention. Separating efficacy from safety, the direct clinical endpoints and mortality benefit merit A with 95 points.
ads claimPromotion can simplify the result into universal superiority over clopidogrel with no additional bleeding concern. The benefit arose within an aspirin-based acute-coronary-syndrome strategy, and non-CABG bleeding, dyspnea, revascularization strategy, individual bleeding risk, and concomitant medicines still matter.
Useful facts when choosing a product
- Ticagrelor is an oral prescription drug that reversibly inhibits the platelet P2Y12 receptor. In acute coronary syndrome, a common regimen is a 180-mg loading dose followed by 90 mg twice daily; the current label and treatment strategy determine the exact dose and duration.
- PLATO established efficacy against clopidogrel on a background of aspirin. Low-dose maintenance aspirin is generally used, and unplanned interruption of antiplatelet therapy can increase thrombotic risk.
- The drug is unsuitable in active pathological bleeding or a history of intracranial hemorrhage, and the treating clinician should set any preoperative interruption. Strong CYP3A inhibitors and inducers also require interaction review.
- Bleeding is the principal safety issue, and dyspnea, ventricular pauses or bradyarrhythmia, and increases in uric acid or creatinine can occur. Overall major bleeding was similar in PLATO, but non-CABG major bleeding was more frequent with ticagrelor.
What the research actually shows
Wallentin and the PLATO Investigators randomized 18,624 patients with acute coronary syndrome, including differing ST-segment presentations and initial management plans, to ticagrelor with a 180-mg loading dose followed by 90 mg twice daily or clopidogrel with a 300-to-600-mg loading dose followed by 75 mg daily; both groups received aspirin. At 12 months, the primary composite was 9.8% versus 11.7%, HR 0.84; myocardial infarction was 5.8% versus 6.9%, vascular death was 4.0% versus 5.1%, and all-cause death was 4.5% versus 5.9%, HR 0.78. Stroke alone was not reduced, so the phrase 'cardiovascular death, myocardial infarction, or stroke reduction' refers to the three-event composite rather than each component separately. Becker and colleagues' PLATO bleeding analysis found similar overall major bleeding but more non-CABG major bleeding. The verdict therefore records A efficacy alongside separate caution for bleeding, dyspnea, and bradycardia.
Why this is classified as A (95)
In PLATO's 18,624 participants, the 12-month composite of cardiovascular death, myocardial infarction, or stroke was 9.8% versus 11.7%, HR 0.84, and all-cause mortality also fell from 5.9% to 4.5%, HR 0.78. These direct hard endpoints and mortality benefit in a very large double-blind randomized trial support A with 95 points. Similar overall major bleeding does not establish safety equivalence for every type of bleeding; non-CABG bleeding, dyspnea, and bradycardia remain separate safety issues.
Counterpoint. Evidence fits patients with acute coronary syndrome whose ischemic risk is high enough and bleeding risk acceptable. Older age, low body weight, prior bleeding, anemia, kidney or liver disease, anticoagulant use, and planned surgery can change the agent and duration choice.
Rejudgment record. New verdict — Prioritized a very large double-blind direct-comparison trial in 18,624 patients with acute coronary syndrome that significantly reduced both the composite of cardiovascular death, myocardial infarction, or stroke and all-cause mortality, while evaluating bleeding, dyspnea, and bradycardia separately as safety outcomes
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduced composite risk of cardiovascular death, myocardial infarction, or stroke in acute coronary syndrome | A | Among 18,624 PLATO participants, the direct hard endpoint fell from 11.7% to 9.8%, HR 0.84. |
| Reduced all-cause mortality in acute coronary syndrome | A | All-cause mortality fell significantly from 5.9% to 4.5%, HR 0.78. |
| Reduced cardiovascular death in acute coronary syndrome | A | Vascular death fell from 5.1% to 4.0%, consistent with the all-cause mortality direction. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Study 1 | Multinational randomized double-blind double-dummy active-controlled trial | 18,624 | Supported by AstraZeneca | Twelve-month composite of cardiovascular death, myocardial infarction, or stroke, and all-cause mortality | Composite endpoint 9.8% versus 11.7%, HR 0.84 (95% CI 0.77 to 0.92); all-cause mortality 4.5% versus 5.9%, HR 0.78 (95% CI 0.69 to 0.89). | Pivotal very large hard-endpoint randomized trial |
| Study 2 | Secondary analysis of prespecified centrally adjudicated bleeding outcomes | 18,624 | Supported by AstraZeneca | Overall, CABG-related, non-CABG major, and fatal bleeding | Overall major bleeding was similar, but non-CABG major bleeding was more frequent with ticagrelor, defining the efficacy-safety trade-off. | Key separate safety analysis |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-22).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-22 · Corrections: none
Cite this verdict
[Chamgap] Ticagrelor x reduced cardiovascular events and all-cause mortality in acute coronary syndrome — Evidence Grade A·95. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/heart/ticagrelor-aspirin-acute-coronary-syndrome-cardiovascular-events-mortality/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.